Infliximab (Remicade, Inflectra, Renflexis, Avsola, Infliximab)_Non-onc

Covers infliximab (Remicade, Inflectra, Renflexis, Avsola) for the listed FDA‑approved indications (Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis) and specified off‑label compendial uses; indications not listed are excluded. Key requirements include indication‑specific prior therapy trials/intolerance documentation, age limits, prescribing or consultation by specified specialists, objective findings where required, adherence to dosing/frequency limits (with up to 10 mg/kg allowed with justification) and documentation of clinical response for reauthorization (GVHD initial approval limited to 1 month).

"Crohn's disease (FDA-approved)"

Sign up to see full coverage criteria, indications, and limitations.